Hong Kong Expands Clinical Trial of "Histotripsy" Focused Ultrasound for Renal Cancer; Li Ka Shing Foundation Advances Asia's First Safety Validation
Hong Kong is expanding clinical trials of histotripsy, a non-invasive tumor treatment. The CUHK Medical Center, Gleneagles Hospital Hong Kong, and Hong Kong Sanatorium & Hospital will conduct trials targeting 30 kidney cancer patients. The Li Ka Shing Foundation stated that this initiative aims to make Hong Kong the first city in Asia to verify the safety and efficacy of this technology in treating kidney diseases.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
CNBC: Colom leads by 2,607 votes in Mississippi Senate race, race uncalled
-
2
RTHK: U.S. stocks closed lower on Tuesday, with the Dow down 0.3% and the Nasdaq down 0.7%.
-
3
Financial Times: Anthropic's underwriting banks prepare to boost IPO valuation to at least $1.5 trillion
-
4
Al Jazeera: Meta Expands AI Age Verification, Rolling Out Globally on Instagram while Threads Rollout Remains Planned
-
5
Nikkei Stock Average flat at 60,451.02 as bank and pharma gains offset tech and machinery losses
-
6
Hong Kong and mainland Chinese stocks opened lower, weighed down by higher-than-expected US inflation and escalating interest rate hike expectations.
-
7
Al Jazeera: UKMTO receives report of incident involving oil tanker in Strait of Hormuz, details unclear
-
8
Hong Kong's Insurance Authority (IA) has prohibited Lim Ka Kit from engaging in insurance intermediary business for nine months.
-
9
Al Jazeera: Iran denies holding talks with the US
-
10
New York State's AI safety bill has officially taken effect, requiring companies such as OpenAI and Anthropic to register and disclose their safety practices.
Markets Today
Recommended Reading


